Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?

Molecular Cancer Research

Volumn 4, Issue 8, 2006, Pages 563-573

  Gaymes, Terry J ^a   Padua, Rose Ann ^a,b   Pla, Marika ^b   Orr, Stephen ^a   Omidvar, Nader ^c   Chomienne, Christine ^b   Mufti, Ghulam J ^a   Rassool, Feyruz V ^a,d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APICIDIN; ATM PROTEIN; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BUTYRATES; CELL CYCLE PROTEINS; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA DAMAGE; DNA-BINDING PROTEINS; GAMMA RAYS; HISTONE DEACETYLASES; HISTONES; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; MICE; MICE, TRANSGENIC; ORGAN SPECIFICITY; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RNA INTERFERENCE; STAUROSPORINE; TRANSFECTION; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 33748427812     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0111     Document Type: Article

References (36)

1. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
2. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93.
3. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004;91:137-68.
4. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
5. Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br J Haematol 2002;118:714-27.
6. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
7. Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 2003;63:2891-7.
8. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78.
9. Amin HM, Saeed S, Alkan S. Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol 2001;115:287-97.
10. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84.
11. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005;11:71-6.
12. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
13. Thiriet C, Hayes JJ. Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 2005;18:617-22.
14. Jeggo PA. DNA double strand breakage and repair. In: Hall JC, Dunlap JC, Friedmann T, Gianelli F, editors. Advances in Genetics. Philadelphia: Academic Press Inc. 1998;38:185-218.
15. Raderschall E, Golub EI, Haaf T. Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. Proc Natl Acad Sci U S A 1999;96:1921-6.
16. Brady N, Gaymes TJ, Cheung M, Mufti GJ, Rassool FV. Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins. Cancer Res 2003;63:1798-805.
17. Rassool FV, North PS, Mufti GJ, Hickson ID. Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells. Oncogene 2003;22:8749-57.
18. Fernandez-Capetillo O, Celeste A, Nussenzweig A. Focusing on foci: H2AX and the recruitment of DNA-damage response factors. Cell Cycle 2003;2:426-7.
19. Sedelnikova OA, Pilch DR, Redon C, Bonner WM. Histone H2AX in DNA damage and repair. Cancer Biol Ther 2003;2:233-5.
20. Brown D, Kogan S, Lagasse E, et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:2551-6.
21. Lallemand-Breitenbach V, Guillemin MC, Janin A, et al. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-52.
22. Zhu J, Lallemand-Breitenbach V, de The H. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission. Oncogene 2001;20:7257-65.
23. 3-induced PML or PML/retinoic acid receptor α degradation. J Exp Med 2001;193:1361-71.
24. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
25. Celeste A, Difilippantonio S, Difilippantonio MJ, et al. H2AX haplo-insufficiency modifies genomic stability and tumor susceptibility. Cell 2003;114:371-83.
26. Malumbres M, Hunt SL, Sotillo R, et al. Driving the cell cycle to cancer. Adv Exp Med Biol 2003;532:1-11.
27. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-63.
28. Waxman S, Huang Y, Scher BM, Scher M. Enhancement of differentiation and cytotoxicity of leukemia cells by combinations of fluorinated pyrimidines and differentiation inducers: development of DNA double-strand breaks. Biomed Pharmacother 1992;46:183-92.
29. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005;18:601-7.
30. Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001;20:5695-707.
31. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:673-8.
32. Rahmani M, Reese E, Dai Y, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005;65:2422-32.
33. Early A, Drury LS, Diffley JF. Mechanisms involved in regulating DNA replication origins during the cell cycle and in response to DNA damage. Philos Trans R Soc Lond B Biol Sci 2004;359:31-8.
34. Weinreich M, Palacios DeBeer MA, Fox CA. The activities of eukaryotic replication origins in chromatin. Biochim Biophys Acta 2004;1677:142-57.
35. Fanidi A, Harrington EA, Evan GI. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992;359:554-6.
36. Omidvar N, Pearn L, Burnett AK, Darley RL. Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras. Mol Cell Biol 2006;26:3966-75.